MI Tumor Seek Hybrid
Use
MI Tumor Seek Hybrid is a laboratory developed test (LDT) that performs high-throughput Next-Generation Sequencing (NGS) to capture both DNA and RNA, combining Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS) of over 23,000 genes. It provides a comprehensive molecular blueprint to guide clinical decisions, helping to confirm diagnosis and optimize therapy selection using predictive AI signatures like Caris GPSai and FOLFIRSTai.
Special Instructions
Not provided.
Limitations
The NGS process requires specific sample conditions, including a minimum of 20% tumor nuclei in specimens. The successful testing rate might be impacted by small tumor samples or low-quality specimens.
Methodology
NGS
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Submit in 10% neutral buffered formalin from fresh tissue, core needle biopsy, bone / bone metastasis.
Other tests from different labs that may be relevant